Key result
Non-vitamin K antagonist oral anticoagulants are as effective as warfarin for preventing recurrent venous thromboembolism and reduce the risk of major bleeding events.
Why the study?
Previous trials comparing non-vitamin K antagonist oral anticoagulants and warfarin for acute venous thromboembolism yielded incomplete results.
Do non-vitamin K antagonist oral anticoagulants reduce recurrent venous thromboembolism and bleeding events compared to warfarin in adult patients with venous thromboembolism?
Meta-Analysis (n=29,879)
Yes
Do non-vitamin K antagonist oral anticoagulants reduce recurrent venous thromboembolism and bleeding events compared to warfarin in adult patients with venous thromboembolism?
In patients with venous thromboembolism, NOACs are as effective as warfarin for preventing recurrent VTE while significantly reducing the risk of major bleeding.
Answers are grounded in this paper and cite their sources.
NOACs match warfarin efficacy with lower major bleeding; reinforces first-line preference in acute VTE.
OBJECTIVE: Several trials had compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin for acute venous thromboembolism, but the results were incomplete. This updated review comprehensively assessed the efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism. DESIGN: Meta-analysis of randomised control trials. Six databases were searched from January 2000 to December 2018. SETTING: Adult patients had got non-vitamin K antagonist oral anticoagulants or warfarin for venous thromboembolism. PARTICIPANTS: Randomised control trials that compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin. MAIN OUTCOME MEASURES: The efficacy and safety of non-vitamin K antagonist oral anticoagulants . RESULTS: Seven studies involving 29,879 cases were included, among which 14,943 cases were assigned to non-vitamin K antagonist oral anticoagulants group and 14,936 cases to warfarin group. Meta-analysis showed that compared with warfarin, recurrent venous thromboembolism (odds ratio 0.94 [95% confidence interval 0.81 to 1.11]), death related to venous thromboembolism or fatal pulmonary embolism (odds ratio 1.00 [95% confidence interval 0.63 to 1.60]), symptomatic deep-vein thrombosis (odds ratio 0.88 [95% confidence interval 0.72 to 1.09]), symptomatic nonfatal pulmonary embolism (odds ratio 1.03 [(95% confidence interval 0.82 to 1.30]) and all deaths (odds ratio 0.92 [95% confidence interval 0.76 to 1.12]) are similar in non-vitamin K antagonist oral anticoagulants group, but major bleeding event (odds ratio 0.61 [95% confidence interval 0.50 to 0.75]) and clinically relevant non-major bleeding event (odds ratio [95% confidence interval 0.53 to 0.85]) are less in non-vitamin K antagonist oral anticoagulants group. . CONCLUSIONS: For the treatment of venous thromboembolism, non-vitamin K antagonist oral anticoagulants is as effective as warfarin, and has a better safety profile than warfarin.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2021) conducted a meta-analysis in Venous thromboembolism (n=29,879). Non-vitamin K antagonist oral anticoagulants vs. Warfarin was evaluated on Recurrent venous thromboembolism (OR 0.94, 95% CI 0.81 to 1.11, p=0.47). Non-vitamin K antagonist oral anticoagulants are as effective as warfarin for preventing recurrent venous thromboembolism and reduce the risk of major bleeding events.
Synapse has enriched 10 related papers. Consider them for comparative context: